

**DEPARTMENT OF HEALTH AND HUMAN SERVICES
OFFICE OF DIRECTOR**

ACTION REFERRAL

TO <i>Myers</i>	DATE <i>8-26-08</i>
--------------------	------------------------

DIRECTOR'S USE ONLY	ACTION REQUESTED
1. LOG NUMBER <i>100109</i>	<input type="checkbox"/> Prepare reply for the Director's signature DATE DUE _____
2. DATE SIGNED BY DIRECTOR <i>cc: Ms. Forkner Depo</i> 	<input type="checkbox"/> Prepare reply for appropriate signature DATE DUE _____
	<input type="checkbox"/> FOIA DATE DUE _____
	<input checked="" type="checkbox"/> Necessary Action

APPROVALS <small>(Only when prepared for director's signature)</small>	APPROVE	* DISAPPROVE <small>(Note reason for disapproval and return to preparer.)</small>	COMMENT
1.			
2.			
3.			
4.			

Pfizer

Unit of Ortho-McNeil, Inc.

Log: MYUS
C: of, vps
MLC: KCI

August, 22, 2008

1000 US Highway 202 South
P.O. Box 300
Raritan, NJ 08869-0302
908-218-6000 Telephone
www.pficara.com

RECEIVED

AUG 26 2008

Department of Health & Human Services
OFFICE OF THE DIRECTOR

Emma Forkner, Director
South Carolina Department of Health and Human Services
P.O. Box 8206
Columbia, SC 29202

Director Forkner,

Recently our State Government Affairs Director and Strategic Market Director meet with Mr. Jim Assey to discuss our intentions to submit a revised offer on Levaquin to First Health. We would like to formally acknowledge our intention to submit revised offers-pricing to First Health as part of the regular annual bidding &-solicitation process for the National Medicaid Pooling Initiative ("NMPPI"). The revised & enhanced offer on Levaquin will allow South Carolina Medicaid to secure or implement the following:

- o An increase in overall rebates on all oral dosage strengths to 77% (statutory & supplemental combined)
- o Ability to implement a step edit on 250mg for GU infections
- o Quantity Limit (QL) on 750 mg Rx's for five days of therapy
- o Immediate effective date (OMJPI will make pricing effective Oct, 2008)

We appreciate any consideration by the state of South Carolina in delaying any PDL decisions on Levaquin until the NMPPI annual bidding process is re-opened in October, 2008. At that time our enhanced offer will be presented to and made available through First Health.

Sincerely,



Catherine Owen
Director of Marketing
Pfizer, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
1000 Route 202 South,
Raritan, NJ 08869, USA.

Cc: James Assey, Pharmacy Director, Director Health & Human Services
George Irving, J&J State Government Affairs

**DEPARTMENT OF HEALTH AND HUMAN SERVICES
OFFICE OF DIRECTOR**

ACTION REFERRAL

TO Myers DATE 8-26-08

*copy to Purnton
Dr Purnton*

DIRECTOR'S USE ONLY	ACTION REQUESTED
1. LOG NUMBER <u>000109</u>	<input type="checkbox"/> Prepare reply for the Director's signature DATE DUE _____
2. DATE SIGNED BY DIRECTOR <u>cc: Mrs. Forkner, Depo</u> <u>48</u>	<input type="checkbox"/> Prepare reply for appropriate signature DATE DUE _____
	<input checked="" type="checkbox"/> Necessary Action DATE DUE _____

APPROVALS <small>(Only when prepared for director's signature)</small>	APPROVE	* DISAPPROVE <small>(Note reason for disapproval and return to preparer.)</small>	COMMENT
1.			
2.			
3.			
4.			